Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing

V. Sykorova, S. Dvorakova, J. Vcelak, E. Vaclavikova, T. Halkova, D. Kodetova, P. Lastuvka, J. Betka, P. Vlcek, M. Reboun, R. Katra, B. Bendlova,

. 2015 ; 35 (4) : 2029-2036.

Language English Country Greece

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16000173

Grant support
NT13901 MZ0 CEP Register

BACKGROUND: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are very rare tumors with extremely aggressive behavior. Their comprehensive genetic background is still unclear. Some of the main genetic changes of differentiated thyroid carcinomas, such as mutations in BRAF and RAS genes, as well as changes in CTNNB1, PIK3CA, TP53, AXIN1, PTEN or APC genes leading to the dedifferentiation of the tumors, are described. MATERIALS AND METHODS: DNAs from fresh frozen thyroid tissues of 3 PDTCs and 5 ATCs were extracted. The next-generation sequencing (NGS) approach was used to target 94 genes involved in cancer. The samples were prepared using a TruSight Cancer panel and sequenced with a MiSeq sequencer. Analysis of variants was performed by the MiSeq Reporter and NextGENe software and stringent criteria for prioritization of the variants were used in the Illumina VariantStudio software. RESULTS: Using NGS, we identified 26 genetic changes in 18 genes, novel variants included. CONCLUSION: NGS is a useful tool for searching for new variants and genes involved in PDTC and ATC. It seems that each of these rare tumor types has its own specific genetic background. These data could be helpful for recognizing new genetic markers and targets for future personalized therapy.

000      
00000naa a2200000 a 4500
001      
bmc16000173
003      
CZ-PrNML
005      
20200121084526.0
007      
ta
008      
160108s2015 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)25862857
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Sýkorová, Vlasta $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic vsykorova@endo.cz. $7 xx0118026
245    10
$a Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing / $c V. Sykorova, S. Dvorakova, J. Vcelak, E. Vaclavikova, T. Halkova, D. Kodetova, P. Lastuvka, J. Betka, P. Vlcek, M. Reboun, R. Katra, B. Bendlova,
520    9_
$a BACKGROUND: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are very rare tumors with extremely aggressive behavior. Their comprehensive genetic background is still unclear. Some of the main genetic changes of differentiated thyroid carcinomas, such as mutations in BRAF and RAS genes, as well as changes in CTNNB1, PIK3CA, TP53, AXIN1, PTEN or APC genes leading to the dedifferentiation of the tumors, are described. MATERIALS AND METHODS: DNAs from fresh frozen thyroid tissues of 3 PDTCs and 5 ATCs were extracted. The next-generation sequencing (NGS) approach was used to target 94 genes involved in cancer. The samples were prepared using a TruSight Cancer panel and sequenced with a MiSeq sequencer. Analysis of variants was performed by the MiSeq Reporter and NextGENe software and stringent criteria for prioritization of the variants were used in the Illumina VariantStudio software. RESULTS: Using NGS, we identified 26 genetic changes in 18 genes, novel variants included. CONCLUSION: NGS is a useful tool for searching for new variants and genes involved in PDTC and ATC. It seems that each of these rare tumor types has its own specific genetic background. These data could be helpful for recognizing new genetic markers and targets for future personalized therapy.
650    _2
$a nádorové biomarkery $x genetika $x izolace a purifikace $7 D014408
650    _2
$a buněčná diferenciace $x genetika $7 D002454
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    _2
$a nádorové proteiny $x genetika $7 D009363
650    _2
$a fosfohydroláza PTEN $x genetika $7 D051059
650    _2
$a fosfatidylinositol-3-kinasy $x genetika $7 D019869
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a anaplastický karcinom štítné žlázy $x genetika $x patologie $7 D065646
650    _2
$a nádory štítné žlázy $x genetika $x patologie $7 D013964
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dvořáková, Šárka $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic. $7 xx0080456
700    1_
$a Včelák, Josef, $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic. $d 1971- $7 xx0107261
700    1_
$a Václavíková, Eliška $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic. $7 xx0228492
700    1_
$a Hálková, Tereza $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic. $7 xx0249425
700    1_
$a Nováková Kodetová, Daniela, $u Departments of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic. $d 1953- $7 jo2002104665
700    1_
$a Laštůvka, Petr, $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic. $d 1973- $7 xx0061330
700    1_
$a Betka, Jan, $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic. $d 1949- $7 jn20000400169
700    1_
$a Vlček, Petr, $u Department of Nuclear Medicine and Endocrinology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic. $d 1961- $7 xx0003505
700    1_
$a Řeboun, Martin $u Institute of Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague 2, Czech Republic. $7 xx0229675
700    1_
$a Katra, Rami $u Department of ENT, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague 5, Czech Republic. $7 xx0228242
700    1_
$a Bendlová, Běla, $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague 1, Czech Republic. $d 1962- $7 jo20000074069
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 35, č. 4 (2015), s. 2029-2036
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25862857 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20200121084903 $b ABA008
999    __
$a ok $b bmc $g 1102454 $s 924379
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 35 $c 4 $d 2029-2036 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
GRA    __
$a NT13901 $p MZ0
LZP    __
$a Pubmed-20160108

Find record

Citation metrics

Logged in users only

Archiving options